RT Journal Article
SR Electronic
T1 Exploring novel risk loci for heart failure and the shared genetic etiology with blood lipids, blood pressure, and blood glucose: a large-scale multi-trait association analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.20.23300280
DO 10.1101/2023.12.20.23300280
A1 Zhu, Yanchen
A1 Wang, Yahui
A1 Cui, Zhaorui
A1 Liu, Fani
A1 Hu, Jiqiang
YR 2023
UL http://medrxiv.org/content/early/2023/12/21/2023.12.20.23300280.abstract
AB Background The comprehensive exploration of genomic risk loci for heart failure (HF) remains constrained, and the genetic role of blood lipids (BL), blood pressure (BP) and blood glucose (BG) in HF has not been fully characterized.Methods We first assessed the global and local genetic correlations between HF and the quantitative traits of BL, BP, and BG. We then employed multi-trait association analysis and multi-trait colocalization analysis to identify novel and pleiotropic genomic risk loci for HF. Furthermore, we explored potential genes, pathways, tissues, and cells associated with HF involving BL, BP, and BG. Lastly, we investigated potential therapeutic targets for HF.Findings We found extensive global and local genetic correlations between HF and the traits of BL, BP, and BG. Multi-trait association analysis successfully identified 154 novel genomic risk loci for HF. Multi-trait colocalization analysis further revealed 46, 35, and 14 co-localized loci shared by HF with BL, BP, and BG, respectively. We found that the loci shared by HF with these traits rarely overlapped, indicating distinct shared mechanisms. Gene-mapping, gene-based, and transcriptome-wide association analyses prioritized noteworthy candidate genes (such as LPL, GRK5, and TNNC1) for HF. In enrichment analysis, HF exhibited comparable characteristics with cardiovascular traits and metabolic correlated to BL, BP, and BG. We provided genetic evidence for putative drugs, and highlighted 33 robust potential protein targets.Interpretation These findings will provide biological insights into the pathogenesis for HF, and benefit the development of preventive or therapeutic drugs for HF.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Capital's Funds for Health Improvement and Research (2020-2-4203).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were as following: The GWAS summary statistics for heart failure and blood pressure used in this study are deposited in the GWAS Catalog (https://www.ebi.ac.uk/gwas/) and the accession codes are as follows: HF (GCST009541),SBP (GCST006624), DBP (GCST006630), and PP (GCST006629).Summary-level data from Global Lipids Genetics Consortium(GLGC) for blood lipids are available as follows: https://csg.sph.umich.edu/willer/public/glgc-lipids2021, and additional lipids traits ( APOA1 [ieu-b-107] and APOB [ieu-b-108]) are available through the IEU Open GWAS database. Data for blood glucose can be obtained from UK Biobank-Neale lab via http://www.nealelab.is/uk-biobank. The pQTL summary statistics are acquired from the UK Biobank Pharma Proteomics Project (UKB-PPP) through the website https://www.synapse.org, and from deCODE genetics via http://www.decode.com. Phenome-wide summary statistics for the UK Biobank can be accessed at https://www.leelabsg.org/resources.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author(hujiqiang{at}bucm.edu.cn).